

Docket No. 2026-4124US1

PATENT

C<sup>2</sup> 3<sup>17</sup>. (Amended) The immunogenic peptide of claim <sup>2</sup>16 having the sequence KTWGQYWQV (SEQ.ID.NO:46), KTWGQYWQVL (SEQ ID NO:47), ITDQVPFSV (SEQ ID NO:48) [and]; or TITDQVPFSV (SEQ ID NO:49).

C<sup>3</sup> 5 19. (Amended) The immunogenic peptide of claims <sup>2</sup>16, <sup>3</sup>17, or <sup>4</sup>18 wherein said peptide contains at least one amino acid modification of said gp100 sequence.

C<sup>4</sup> 9 22. (Amended) An immunogenic peptide having the [a] formula selected from the group consisting of  $X_1X_2X_3GQYWQX_4$ ,  $X_1X_2X_3QVPFSX_4$  and  $X_1X_2X_3PGPVTX_4$  wherein:

$X_1$  is any naturally occurring amino acid;

$X_2$  is any hydrophobic aliphatic amino acid;

$X_3$  is any naturally occurring amino acid; and

$X_4$  is any [a] hydrophobic aliphatic amino acid.

9 23. (Amended) The peptide of claim <sup>8</sup>22 wherein the amino acid for  $X_1$  is selected from the group consisting of methionine, leucine, alanine, glycine, threonine, isoleucine, valine tyrosine, serine, tryptophan, phenylalanine, serine, lysine [or] and aspartic acid.

10 24. (Amended) The peptide of claim <sup>8</sup>22 wherein  $X_2$  is selected from the group consisting of methionine, leucine, alanine, glycine, isoleucine, valine [or] and threonine.

11 25. (Amended) The peptide of claim <sup>8</sup>22 wherein  $X_3$  is selected from the group consisting of methionine, leucine, alanine, glycine, threonine, isoleucine, tyrosine, valine, tryptophan, phenylalanine, serine, lysine [or] and aspartic acid.

Docket No. 2026-4124US1

PATENT

C4  
12 26. (Amended) The peptide of claim <sup>B</sup>22 wherein X<sub>4</sub> is selected from the group consisting of methionine, leucine, alanine, glycine, isoleucine, valine [or] and threonine.

14 28. (Amended) The immunogenic peptide of [any one of claims 1, 9,] claim 15 or claim <sup>B</sup>22 wherein said peptide is a native, synthetic or recombinant peptide.

C5  
29. (Amended) A pharmaceutical composition comprising the peptides of [any one of claims 1, 9,] claim 15 or claim 22 and an acceptable excipient, diluent or carrier.

Sub D3  
30. (Amended) A method of [preventing or] treating melanoma in a mammal comprising administering the pharmaceutical composition of claim 29 to a mammal in an effective amount to stimulate the production of [protective antibodies or] immune cells.

31. (Amended) An immunogenic composition [A vaccine] for immunizing a mammal comprising a peptide according to [any one of claims 1, 9,] claim 15 or claim 22 in a pharmacologically acceptable carrier.

REMARKS

Claims 1-38 are pending in this application. Claims 15-18, 22-26 and 27-31 stand rejected, claims 19-21 are objected to, and claims 1-14, 27-31 and 32-38 are withdrawn from consideration. Support for the amendments may be found throughout the specification. Reconsideration of the application as amended is respectfully requested.